JP2018520091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520091A5 JP2018520091A5 JP2017557287A JP2017557287A JP2018520091A5 JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5 JP 2017557287 A JP2017557287 A JP 2017557287A JP 2017557287 A JP2017557287 A JP 2017557287A JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- activatable antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022910A JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156835P | 2015-05-04 | 2015-05-04 | |
| US62/156,835 | 2015-05-04 | ||
| US201562220805P | 2015-09-18 | 2015-09-18 | |
| US62/220,805 | 2015-09-18 | ||
| PCT/US2016/030785 WO2016179285A1 (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Division JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520091A JP2018520091A (ja) | 2018-07-26 |
| JP2018520091A5 true JP2018520091A5 (OSRAM) | 2019-06-20 |
| JP7028648B2 JP7028648B2 (ja) | 2022-03-02 |
Family
ID=55967468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557287A Expired - Fee Related JP7028648B2 (ja) | 2015-05-04 | 2016-05-04 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10745481B2 (OSRAM) |
| EP (2) | EP3292150B1 (OSRAM) |
| JP (2) | JP7028648B2 (OSRAM) |
| KR (1) | KR20180010203A (OSRAM) |
| CN (2) | CN107849133B (OSRAM) |
| AU (1) | AU2016257929B2 (OSRAM) |
| BR (1) | BR112017023872A2 (OSRAM) |
| CA (1) | CA2984948A1 (OSRAM) |
| DK (1) | DK3292150T3 (OSRAM) |
| EA (1) | EA201792414A1 (OSRAM) |
| ES (1) | ES2796698T3 (OSRAM) |
| HR (1) | HRP20200721T1 (OSRAM) |
| HU (1) | HUE049866T2 (OSRAM) |
| IL (2) | IL292798A (OSRAM) |
| MX (2) | MX388350B (OSRAM) |
| PL (1) | PL3292150T3 (OSRAM) |
| PT (1) | PT3292150T (OSRAM) |
| RS (1) | RS60222B1 (OSRAM) |
| SG (2) | SG10202110908WA (OSRAM) |
| WO (1) | WO2016179285A1 (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| EP3628328B1 (en) * | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP7028648B2 (ja) | 2015-05-04 | 2022-03-02 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CA3029902A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| KR20230073346A (ko) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| TW202323287A (zh) | 2016-11-28 | 2023-06-16 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| EP3551667A4 (en) | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
| EP3652210A1 (en) * | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| KR20200040819A (ko) | 2017-08-16 | 2020-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| MX2020002198A (es) | 2017-08-30 | 2020-07-20 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| CN111315773A (zh) * | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| WO2019107380A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| MX2020005160A (es) | 2017-11-28 | 2020-08-20 | Chugai Pharmaceutical Co Ltd | Molecula de union a ligando que tiene actividad de union a ligando ajustable. |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン－２ポリペプチド及びその使用方法 |
| SG11202011308VA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CN113260383A (zh) * | 2018-11-02 | 2021-08-13 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
| US12049505B2 (en) | 2018-12-06 | 2024-07-30 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN113614111A (zh) * | 2019-01-14 | 2021-11-05 | 加利福尼亚大学董事会 | 用于调节细胞内化的组合物和方法 |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| JP2022523200A (ja) * | 2019-02-26 | 2022-04-21 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| TW202102270A (zh) | 2019-03-21 | 2021-01-16 | 美商伊繆諾金公司 | 製備細胞結合劑-藥物結合物之方法 |
| KR102212149B1 (ko) * | 2019-03-28 | 2021-02-04 | 부산대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도 |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| US20220226514A1 (en) * | 2019-05-17 | 2022-07-21 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| BR112021023735A2 (pt) | 2019-06-05 | 2022-01-04 | Chugai Pharmaceutical Co Ltd | Molécula de ligação de sítio de clivagem de anti-corpo |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| AU2021254279A1 (en) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| KR20230109669A (ko) * | 2020-11-16 | 2023-07-20 | 더 클리브랜드 클리닉 파운데이션 | T-세포 및 b-세포 매개 장애, 및 t-세포 및 b-세포 암을 치료하기 위한 항-cd6 항체 접합체 |
| WO2022169825A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| KR20240118749A (ko) | 2021-10-15 | 2024-08-05 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 폴리펩타이드 복합체 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250011422A1 (en) * | 2021-11-12 | 2025-01-09 | University Of Florida Research Foundation, Incorporated | Siglec-6 antibodies, derivative compounds and related uses |
| CN114621348B (zh) * | 2022-01-24 | 2023-09-22 | 深圳市乐土生物医药有限公司 | 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体 |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| CN119301151A (zh) | 2022-03-25 | 2025-01-10 | 西托姆克斯治疗公司 | 可激活双锚定掩蔽分子和其使用方法 |
| US20250215110A1 (en) | 2022-04-01 | 2025-07-03 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| US20250230239A1 (en) | 2022-04-01 | 2025-07-17 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023222580A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| KR20250036813A (ko) | 2022-07-12 | 2025-03-14 | 싸이톰스 테라퓨틱스, 인크. | Epcam 면역접합체 및 이의 용도 |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| EP4565690A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025047993A1 (en) * | 2023-08-28 | 2025-03-06 | Pharosgen Co., Ltd. | Anti-doppel antibody drug conjugates |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| AU9127098A (en) | 1997-09-04 | 1999-03-22 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| ES2368387T5 (es) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Anticuerpos terapéuticos y que inducen tolerancia |
| CA2483912A1 (en) | 2002-05-03 | 2003-11-13 | Raven Biotechnologies, Inc. | Alcam and alcam modulators |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| CA2549956C (en) | 2003-12-22 | 2016-04-12 | Glaxo Group Limited | Immunoglobulins |
| EP1930346B1 (en) | 2005-08-29 | 2011-10-19 | Japan Science and Technology Agency | Antibody produced using ostrich and method for production thereof |
| EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF |
| US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
| WO2007063825A1 (ja) | 2005-11-29 | 2007-06-07 | Japan Science And Technology Agency | Cd166に対するモノクローナル抗体およびその産生方法 |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| GB0705775D0 (en) * | 2007-03-26 | 2007-05-02 | Affitech As | Product |
| JP2009055899A (ja) | 2007-08-07 | 2009-03-19 | Igaku Seibutsugaku Kenkyusho:Kk | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| CA2699394C (en) | 2007-09-17 | 2020-03-24 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| ES2562627T3 (es) | 2008-02-20 | 2016-03-07 | Novo Nordisk A/S | Anticuerpos anti-C5aR humanizados |
| CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| US8846870B2 (en) | 2008-12-22 | 2014-09-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-HS6ST2 antibodies and uses thereof |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| ES2641612T3 (es) | 2009-04-17 | 2017-11-10 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| MX2013005046A (es) | 2010-11-03 | 2013-12-12 | Immunogen Inc | Agentes citotoxicos que comprenden nuevos derivados de ansamitocina. |
| AU2012253373A1 (en) | 2011-05-11 | 2013-11-28 | Nanovalent Pharmaceuticals, Inc. | Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor |
| SMT201700467T1 (it) * | 2012-02-24 | 2017-11-15 | Abbvie Stemcentrx Llc | Modulatori di dll3 e metodi di uso |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| SG11201504764SA (en) | 2012-12-19 | 2015-07-30 | Amplimmune Inc | Anti-human b7-h4 antibodies and their uses |
| JP6605957B2 (ja) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス，インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| CA2913732A1 (en) * | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| BR112016001611B1 (pt) * | 2013-07-25 | 2024-01-09 | Cytomx Therapeutics, Inc | Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico |
| JP7028648B2 (ja) | 2015-05-04 | 2022-03-02 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| US10765742B2 (en) | 2015-07-17 | 2020-09-08 | The Trustees Of Columbia University In The City Of New York | Methods of treating CD166-expressing cancer |
| EP3371301A4 (en) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS |
| WO2017218750A1 (en) | 2016-06-15 | 2017-12-21 | The Cleveland Clinic Foundation | Novel anti-cd6 antibodies for treating t-cell mediated conditions |
| JP6183523B2 (ja) | 2016-09-14 | 2017-08-23 | 株式会社アンセイ | 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構 |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| US11376332B2 (en) | 2016-10-15 | 2022-07-05 | Baylor College Of Medicine | Platform for enhanced targeted delivery |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EP3652210A1 (en) | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| MX2020002198A (es) | 2017-08-30 | 2020-07-20 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. |
| CN113260383A (zh) | 2018-11-02 | 2021-08-13 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
| JP2022523200A (ja) | 2019-02-26 | 2022-04-21 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 |
-
2016
- 2016-05-04 JP JP2017557287A patent/JP7028648B2/ja not_active Expired - Fee Related
- 2016-05-04 SG SG10202110908WA patent/SG10202110908WA/en unknown
- 2016-05-04 US US15/146,603 patent/US10745481B2/en active Active
- 2016-05-04 CN CN201680038634.3A patent/CN107849133B/zh not_active Expired - Fee Related
- 2016-05-04 ES ES16722502T patent/ES2796698T3/es active Active
- 2016-05-04 EA EA201792414A patent/EA201792414A1/ru unknown
- 2016-05-04 EP EP16722502.8A patent/EP3292150B1/en active Active
- 2016-05-04 BR BR112017023872A patent/BR112017023872A2/pt not_active IP Right Cessation
- 2016-05-04 RS RS20200511A patent/RS60222B1/sr unknown
- 2016-05-04 PT PT167225028T patent/PT3292150T/pt unknown
- 2016-05-04 MX MX2017014136A patent/MX388350B/es unknown
- 2016-05-04 HR HRP20200721TT patent/HRP20200721T1/hr unknown
- 2016-05-04 IL IL292798A patent/IL292798A/en unknown
- 2016-05-04 PL PL16722502T patent/PL3292150T3/pl unknown
- 2016-05-04 DK DK16722502.8T patent/DK3292150T3/da active
- 2016-05-04 SG SG10201913767VA patent/SG10201913767VA/en unknown
- 2016-05-04 EP EP20155149.6A patent/EP3708585A1/en not_active Withdrawn
- 2016-05-04 KR KR1020177034835A patent/KR20180010203A/ko not_active Abandoned
- 2016-05-04 AU AU2016257929A patent/AU2016257929B2/en not_active Expired - Fee Related
- 2016-05-04 WO PCT/US2016/030785 patent/WO2016179285A1/en not_active Ceased
- 2016-05-04 CN CN202210950237.0A patent/CN115340607A/zh active Pending
- 2016-05-04 CA CA2984948A patent/CA2984948A1/en active Pending
- 2016-05-04 HU HUE16722502A patent/HUE049866T2/hu unknown
-
2017
- 2017-11-02 IL IL255414A patent/IL255414B/en unknown
- 2017-11-03 MX MX2021014735A patent/MX2021014735A/es unknown
-
2019
- 2019-12-20 US US16/723,809 patent/US11753466B2/en active Active
-
2022
- 2022-02-17 JP JP2022022910A patent/JP2022065115A/ja not_active Withdrawn
-
2023
- 2023-07-18 US US18/354,353 patent/US20240076374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520091A5 (OSRAM) | ||
| JP2018520991A5 (OSRAM) | ||
| JP2018520092A5 (OSRAM) | ||
| EP3292149B1 (en) | Activatable anti-cd71 antibodies, and methods of use thereof | |
| Carter et al. | Antibody-drug conjugates for cancer therapy | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| JP2017522871A5 (OSRAM) | ||
| JP2018516539A (ja) | 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 | |
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| JP7547205B2 (ja) | 抗ｈｅｒ２バイパラトピック抗体－薬物コンジュゲート及び使用方法 | |
| CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
| CN105288644A (zh) | 抗体-药物缀合物 | |
| Zhang et al. | Novel development strategies and challenges for anti-Her2 antibody-drug conjugates | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| Jin et al. | An anti-EGFR× cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations | |
| Chen et al. | Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG× CD20) | |
| CN112175082B (zh) | 抗叶酸受体α抗体、其缀合物及其用途 | |
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 | |
| JPWO2021251459A5 (OSRAM) | ||
| Zhong et al. | A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| AU2018285523A1 (en) | Antibody drug conjugates that bind LGR5 | |
| JPWO2020176497A5 (OSRAM) |